JP5406215B2 - ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物 - Google Patents
ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物 Download PDFInfo
- Publication number
- JP5406215B2 JP5406215B2 JP2010544436A JP2010544436A JP5406215B2 JP 5406215 B2 JP5406215 B2 JP 5406215B2 JP 2010544436 A JP2010544436 A JP 2010544436A JP 2010544436 A JP2010544436 A JP 2010544436A JP 5406215 B2 JP5406215 B2 JP 5406215B2
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- quinoline
- pyrimido
- dione
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(c(*)c1**N2C(N3*)=*)c(*)c(nc4)c1c2c4C3=* Chemical compound *c(c(*)c1**N2C(N3*)=*)c(*)c(nc4)c1c2c4C3=* 0.000 description 1
- GMEQCFSPZBKXJY-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1N(c(c(cccc1OC)c1nc1)c1C(N1c2cccc(Cl)c2)=O)C1=O)=O Chemical compound CC(C)OC(N(CC1)CCC1N(c(c(cccc1OC)c1nc1)c1C(N1c2cccc(Cl)c2)=O)C1=O)=O GMEQCFSPZBKXJY-UHFFFAOYSA-N 0.000 description 1
- DLVHYSMNJZZBJZ-UHFFFAOYSA-N CCN(C(c(cnc1c2cccc1OC)c2N1C2CCC(C)CC2)=O)C1=O Chemical compound CCN(C(c(cnc1c2cccc1OC)c2N1C2CCC(C)CC2)=O)C1=O DLVHYSMNJZZBJZ-UHFFFAOYSA-N 0.000 description 1
- UUWDCIKSKPEDMO-UHFFFAOYSA-N CCN(C(c(cnc1c2cccc1OC)c2N1C2CCCC2)=O)C1=S Chemical compound CCN(C(c(cnc1c2cccc1OC)c2N1C2CCCC2)=O)C1=S UUWDCIKSKPEDMO-UHFFFAOYSA-N 0.000 description 1
- GPMSLBNLZRLROA-UHFFFAOYSA-N CCN(C(c(cnc1c2cccc1OC)c2N1CC(C)(C)C)=O)C1=O Chemical compound CCN(C(c(cnc1c2cccc1OC)c2N1CC(C)(C)C)=O)C1=O GPMSLBNLZRLROA-UHFFFAOYSA-N 0.000 description 1
- SJGQNDBTUUOYSK-UHFFFAOYSA-N CCN(C(c(cnc1c2cccc1OC)c2N1Cc(cc2)ccc2OC)=O)C1=O Chemical compound CCN(C(c(cnc1c2cccc1OC)c2N1Cc(cc2)ccc2OC)=O)C1=O SJGQNDBTUUOYSK-UHFFFAOYSA-N 0.000 description 1
- SRZNJZKKXAHSLG-UHFFFAOYSA-N COc1cccc2c1ncc(C(N1C3CCCC3)=O)c2N(C2CCCC2)C1=O Chemical compound COc1cccc2c1ncc(C(N1C3CCCC3)=O)c2N(C2CCCC2)C1=O SRZNJZKKXAHSLG-UHFFFAOYSA-N 0.000 description 1
- DFTGKUJJDBYDBZ-UHFFFAOYSA-N COc1cccc2c1ncc(C(N1c3cc(Cl)ccc3)=O)c2N(C(CC2)CCN2C(c2ccccc2)=O)C1=O Chemical compound COc1cccc2c1ncc(C(N1c3cc(Cl)ccc3)=O)c2N(C(CC2)CCN2C(c2ccccc2)=O)C1=O DFTGKUJJDBYDBZ-UHFFFAOYSA-N 0.000 description 1
- VLSIAPYZDCCBPU-UHFFFAOYSA-N COc1cccc2c1ncc(C(N1c3cccc(Cl)c3)=O)c2N(C(CC2)CCC2C(O)=O)C1=O Chemical compound COc1cccc2c1ncc(C(N1c3cccc(Cl)c3)=O)c2N(C(CC2)CCC2C(O)=O)C1=O VLSIAPYZDCCBPU-UHFFFAOYSA-N 0.000 description 1
- PYZDPPRYPHIHCL-UHFFFAOYSA-N COc1cccc2c1ncc(C(N1c3cccc(Cl)c3)=O)c2N(CC(CC2)CCN2S(C)(=O)=O)C1=O Chemical compound COc1cccc2c1ncc(C(N1c3cccc(Cl)c3)=O)c2N(CC(CC2)CCN2S(C)(=O)=O)C1=O PYZDPPRYPHIHCL-UHFFFAOYSA-N 0.000 description 1
- UXQHERGWFNFMGT-UHFFFAOYSA-N Cc1c(C)c(N(C(c(cnc2c3cccc2OC)c3N2C3CCCC3)=O)C2=O)ccc1 Chemical compound Cc1c(C)c(N(C(c(cnc2c3cccc2OC)c3N2C3CCCC3)=O)C2=O)ccc1 UXQHERGWFNFMGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2361708P | 2008-01-25 | 2008-01-25 | |
| US61/023,617 | 2008-01-25 | ||
| PCT/US2009/031819 WO2009094528A1 (en) | 2008-01-25 | 2009-01-23 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510929A JP2011510929A (ja) | 2011-04-07 |
| JP2011510929A5 JP2011510929A5 (OSRAM) | 2012-03-08 |
| JP5406215B2 true JP5406215B2 (ja) | 2014-02-05 |
Family
ID=40901439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544436A Active JP5406215B2 (ja) | 2008-01-25 | 2009-01-23 | ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US7964608B2 (OSRAM) |
| EP (1) | EP2244574B1 (OSRAM) |
| JP (1) | JP5406215B2 (OSRAM) |
| KR (1) | KR101709141B1 (OSRAM) |
| CN (1) | CN101925301B (OSRAM) |
| AU (1) | AU2009206368B2 (OSRAM) |
| BR (1) | BRPI0906809A2 (OSRAM) |
| CA (1) | CA2711576C (OSRAM) |
| EA (1) | EA018462B1 (OSRAM) |
| ES (1) | ES2523169T3 (OSRAM) |
| IL (1) | IL206854A (OSRAM) |
| MA (1) | MA32035B1 (OSRAM) |
| MX (1) | MX2010007768A (OSRAM) |
| NZ (1) | NZ586695A (OSRAM) |
| WO (1) | WO2009094528A1 (OSRAM) |
| ZA (1) | ZA201004818B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009206368B2 (en) * | 2008-01-25 | 2014-12-11 | Vtv Therapeutics Llc | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR090100A1 (es) * | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| CA2898018C (en) | 2013-02-01 | 2021-02-09 | Wellstat Therapeutics Corporation | Substituted quinolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TN2017000485A1 (en) * | 2015-06-17 | 2019-04-12 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| CN109705037A (zh) * | 2019-01-24 | 2019-05-03 | 广西师范大学 | 4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102766496B1 (ko) | 2019-08-09 | 2025-02-10 | 주식회사 엘지에너지솔루션 | 연쇄발화 방지를 위한 에너지 드레인 저항체를 구비한 배터리 팩 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN113861189A (zh) * | 2020-06-29 | 2021-12-31 | Vtv治疗有限责任公司 | 喹啉衍生物，其药学上可接受的盐及其使用方法 |
| CN116529247A (zh) * | 2020-07-28 | 2023-08-01 | 维特卫治疗有限责任公司 | 喹啉衍生物的盐酸盐的晶型 |
| WO2022026350A1 (en) * | 2020-07-28 | 2022-02-03 | Vtv Therapeutics Llc | Crystalline form of hydrochloride salt of quinoline derivative |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN116262750A (zh) * | 2021-12-15 | 2023-06-16 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO162019C (no) | 1983-11-23 | 1989-10-25 | Fujisawa Pharmaceutical Co | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidoiskinolinderivater. |
| US4927820A (en) * | 1988-11-25 | 1990-05-22 | Hoechst Roussel Pharmaceuticals Inc. | Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine |
| JPH0741479A (ja) * | 1993-07-28 | 1995-02-10 | Taisho Pharmaceut Co Ltd | ７−アザプテリジン類およびその製造方法 |
| BR9709105A (pt) * | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv |
| US6930101B1 (en) * | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| US20030207845A1 (en) * | 2001-02-08 | 2003-11-06 | Keating Elizabeth T. | Method and compositions for treating an inflammatory disease |
| EA008108B1 (ru) | 2001-09-19 | 2007-04-27 | Алтана Фарма Аг | Комбинация нспвлс и ингибитора pde-4 |
| TW200306192A (en) * | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| PL193012B1 (pl) * | 2003-06-09 | 2007-01-31 | Univ Medyczny | 3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dion i 3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dion oraz sposób otrzymywania 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dionu i 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dionu |
| TW200726767A (en) | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| AU2009206368B2 (en) * | 2008-01-25 | 2014-12-11 | Vtv Therapeutics Llc | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors |
| CA2753597A1 (en) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Drug combinations containing pde4-inhibitors and nsaids |
| WO2010097334A1 (de) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| US20130225609A1 (en) | 2010-04-08 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists |
| US8877758B2 (en) | 2010-04-08 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists |
-
2009
- 2009-01-23 AU AU2009206368A patent/AU2009206368B2/en active Active
- 2009-01-23 CN CN200980102961.0A patent/CN101925301B/zh active Active
- 2009-01-23 EA EA201070884A patent/EA018462B1/ru not_active IP Right Cessation
- 2009-01-23 MX MX2010007768A patent/MX2010007768A/es active IP Right Grant
- 2009-01-23 ES ES09704760.9T patent/ES2523169T3/es active Active
- 2009-01-23 EP EP09704760.9A patent/EP2244574B1/en active Active
- 2009-01-23 JP JP2010544436A patent/JP5406215B2/ja active Active
- 2009-01-23 NZ NZ586695A patent/NZ586695A/en not_active IP Right Cessation
- 2009-01-23 BR BRPI0906809-0A patent/BRPI0906809A2/pt not_active Application Discontinuation
- 2009-01-23 US US12/532,861 patent/US7964608B2/en active Active
- 2009-01-23 CA CA2711576A patent/CA2711576C/en active Active
- 2009-01-23 WO PCT/US2009/031819 patent/WO2009094528A1/en not_active Ceased
- 2009-01-23 KR KR1020107017176A patent/KR101709141B1/ko active Active
-
2010
- 2010-07-07 IL IL206854A patent/IL206854A/en active IP Right Grant
- 2010-07-08 ZA ZA2010/04818A patent/ZA201004818B/en unknown
- 2010-07-23 MA MA33045A patent/MA32035B1/fr unknown
-
2011
- 2011-03-04 US US13/040,382 patent/US8853226B2/en active Active
-
2012
- 2012-03-02 US US13/410,628 patent/US8329715B2/en active Active
-
2014
- 2014-09-04 US US14/477,302 patent/US9163022B2/en active Active
-
2015
- 2015-09-10 US US14/850,012 patent/US9393245B2/en active Active
-
2016
- 2016-06-16 US US15/184,392 patent/US9687489B2/en active Active
-
2017
- 2017-05-22 US US15/600,942 patent/US9833457B2/en active Active
- 2017-11-01 US US15/800,794 patent/US10085990B2/en active Active
-
2018
- 2018-08-27 US US16/113,327 patent/US10391097B2/en active Active
-
2019
- 2019-07-10 US US16/507,219 patent/US10568888B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5406215B2 (ja) | ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物 | |
| US20250000860A1 (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
| JP2008510770A (ja) | Ｐｌｋ阻害剤としての新規プテリジノン | |
| JP2014531449A (ja) | キナーゼ阻害剤としてのピラゾロ［４，３―ｃ］ピリジン誘導体 | |
| JP6472454B2 (ja) | 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 | |
| JP6322275B2 (ja) | ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン | |
| US8455495B2 (en) | Pyridazino-pyridinone compounds and methods of use | |
| TW202317087A (zh) | 用於治療與sting活性相關病況之化合物及組合物 | |
| HK1147913B (en) | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120123 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130926 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131031 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5406215 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |